Becton Dickinson: Christopher DelOrefice, Christopher Reidy
Becton Dickinson has named Christopher DelOrefice to be the firm's executive vice president and chief financial officer, effective Sept. 6. DelOrefice will succeed Christopher Reidy, who had served as BD's CFO for eight years. He joins the firm from Johnson & Johnson, where he was most recently vice president of investor relations and also served as CFO of J&J's consumer and medical devices segments among other finance positions. Reidy will now become a director of the company formed in connection with the separation of the BD diabetes care business into an independent, publicly traded company.
Adaptive Biotechnologies: Nitin Sood
Adaptive Biotechnologies has appointed Nitin Sood to the newly created position of chief commercial officer. Sood has more than 15 years of experience at life sciences and diagnostics companies, most recently at Guardant Health, where he was senior VP of product development. In his new role, he will oversee sales and marketing of Adaptive's immunoSEQ, clonoSEQ, and T-Detect products. Prior to joining Guardant, Sood was CEO of next-generation sequencing sample prep firm NuGEN. He also previously held roles at PerkinElmer and Agilent Technologies.
ChromaCode: Patrick Balthrop, Kevin O’Boyle
Patrick Balthrop and Kevin O’Boyle have joined the board of directors of molecular diagnostics developer ChromaCode. Balthrop is the former CEO and president of Luminex. He is also chairman of the board at Agendia; chairman of Discovery Life Sciences; and a founding principal of Apalachee Ventures. O’Boyle was most recently chairman of the board at GenMark Diagnostics, which was acquired by Roche in March. He is also currently a member of the board of directors at Nevro and Sientra.
For additional recent items on executive appointments and promotions in omics and molecular diagnostics, please see the People in the News page on our website.